>
Switch to:

Myovant Sciences Earnings Yield (Joel Greenblatt) %

: -15.63% (As of Mar. 2022)
View and export this data going back to 2016. Start your Free Trial

Myovant Sciences's Enterprise Value for the quarter that ended in Mar. 2022 was $1,197.2 Mil. Myovant Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 was $-187.0 Mil. Myovant Sciences's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2022 was -15.63%.

The historical rank and industry rank for Myovant Sciences's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

MYOV' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -24.84   Med: -15.15   Max: -10.11
Current: -15.6

During the past 7 years, the highest Earnings Yield (Joel Greenblatt) of Myovant Sciences was -10.11%. The lowest was -24.84%. And the median was -15.15%.

MYOV's Earnings Yield (Joel Greenblatt) % is ranked worse than
56.17% of 1556 companies
in the Biotechnology industry
Industry Median: -10.11 vs MYOV: -15.60

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Myovant Sciences's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2022 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Myovant Sciences Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Myovant Sciences's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myovant Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Earnings Yield (Joel Greenblatt) %
Premium Member Only Premium Member Only -11.44 -15.90 -38.02 -15.70 -15.63

Myovant Sciences Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Earnings Yield (Joel Greenblatt) % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.70 -14.35 -12.21 -16.34 -15.63

Competitive Comparison

For the Biotechnology subindustry, Myovant Sciences's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Myovant Sciences Earnings Yield (Joel Greenblatt) % Distribution

For the Biotechnology industry and Healthcare sector, Myovant Sciences's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Myovant Sciences's Earnings Yield (Joel Greenblatt) % falls into.



Myovant Sciences Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Myovant Sciencess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2022 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-186.962/1197.21722
=-15.62 %

Myovant Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-187.0 Mil.



Myovant Sciences  (NYSE:MYOV) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Myovant Sciences Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Myovant Sciences Business Description

Myovant Sciences logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2834
Traded in Other Exchanges
Address
11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
Executives
Potter Myrtle S director 10 FINDERNE AVE BRIDGEWATER NJ 08807
Guinan Mark director C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094
Arjona Ferreira Juan Camilo officer: Chief Medical Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Curran Terrie director C/O MYOVANT SCIENCES INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Gulfo Adele M. director ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957
Sebelius Kathleen director C/O DERMIRA, INC. 275 MIDDLEFIELD ROAD, SUITE 150 MENLO PARK CA 94025
Lang Matthew officer: General Counsel & Corp. Secy. C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Sumitomo Chemical Co., Ltd. 10 percent owner 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260
Sumitovant Biopharma Ltd. 10 percent owner C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd 10 percent owner 60 WALL STREET NEW YORK NY 10005
Seely Lynn director, officer: Principal Executive Officer 501 2ND STREET SUITE 211 SAN FRANCISCO CA 94107
Sablich Kim officer: Chief Commercial Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Nomura Hiroshi director C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Torti Frank director 2855 SAND HILL ROAD MENLO PARK CA 94025

Myovant Sciences Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)